Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 11/20 | 0.60 |
| ▸ | CES1 | P23141 | 10/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108031 | 1.00 | CES2 (0.60) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL28138711 | 1.00 | CES2 (0.60) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL1049892 | 1.00 | CES2 (0.60) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11488533 | 0.88 | SMN1; SMN2 (0.59) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11373661 | 0.88 | SMN1; SMN2 (0.59) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11373666 | 0.88 | SMN1; SMN2 (0.59) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11424490 | 0.85 | CES2 (0.54) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11714645 | 0.83 | PARP10 (0.53) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11714663 | 0.83 | PARP10 (0.53) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL28543716 | 0.82 | CES2 (0.50) | CES2CES1MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240168374-A1 | PHOTORESIST COMPOSITION | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2024-05-23 | — | — | US | claimed |
| CN-117142982-A | Synthesis method of 2-iso-nitrosopropiophenone | 沈阳思拓新材料技术有限公司 | 2023-12-01 | — | — | CN | claimed |
| EP-3379248-B1 | ARGINASE ACTIVITY MEASUREMENT METHOD, ARGINASE ACTIVITY DETECTION KIT, ARGINASE-RELATED DISEASE DETECTION KIT, AND ARGINASE INHIBITOR OR ACTIVE AGENT SCREENING METHOD | TOKYO OHKA KOGYO CO LTD (JP) | 2020-09-23 | — | — | EP | claimed |
| EP-3379248-A1 | ARGINASE ACTIVITY MEASUREMENT METHOD, ARGINASE ACTIVITY DETECTION KIT, ARGINASE-RELATED DISEASE DETECTION KIT, AND ARGINASE INHIBITOR OR ACTIVE AGENT SCREENING METHOD | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2018-09-26 | — | — | EP | claimed |
| JP-58039648-A | — | — | None | — | — | JP | disclosed |
| JP-57126451-A | — | — | None | — | — | JP | disclosed |
| JP-3193767-A | — | — | None | — | — | JP | disclosed |
| US-12638708-B2 | Method for manufacturing display device | JAPAN DISPLAY INC. (JP) | 2026-05-26 | — | — | US | disclosed |
| WO-2026105567-A1 | BRANCHED ORGANOPOLYSILOXANE, CURABLE COMPOSITION, AND USE THEREOF | ダウ・東レ株式会社 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026105566-A1 | BRANCHED ORGANOPOLYSILOXANE, CURABLE COMPOSITION, AND USE THEREOF | ダウ・東レ株式会社 | 2026-05-21 | — | — | WO | disclosed |
| CN-122037081-A | Active energy ray-curable composition, cured product, and laminate | 荒川化学工业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-12624174-B2 | Hydrogen-bond enriched ion exchange membranes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-05-12 | — | — | US | disclosed |
| US-4224246-A | Process for the synthesis and separation of the threo and erythro isomers of 2-amino-1-phenyl-1-propanol | INTERNATIONAL MINERALS AND CHEMICAL CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4198421-A | ANTIARTHRITIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-15 | — | — | US | disclosed |
| EP-0005172-A1 | Coumarin derivatives and their use as brightening agents for high molecular organic substances | BAYER AG (DE) | 1979-11-14 | — | — | EP | disclosed |
| US-4144243-A | OPTICAL BRIGHTENERS FOR TEXTILES AND LACQUEARS | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-13 | — | — | US | disclosed |
| US-4006158-A | Fluorescent 1,2,3-triazole derivatives of 3-phenylcoumarin | SANDOZ LTD. (CH) | 1977-02-01 | — | — | US | disclosed |
| US-4005098-A | BRIGHTENING AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-25 | — | — | US | disclosed |
| US-3965094-A | Process for the manufacture of 2-aryl-v-triazole | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-22 | — | — | US | disclosed |
| US-3947412-A | CYCLIZATION IN THE PRESENCE OF HEAVY METALS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12638708-B2 | Method for manufacturing display device | GJB2, PDCD2L, VCL | CES2 959/4885CES1 3297/4885MAPT 254/4885 |
| US-12624174-B2 | Hydrogen-bond enriched ion exchange membranes | SLC9A2, SLC9A3, SLC9A1 | CES2 1474/4885CES1 4082/4885MAPT 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.